Compare NTWK & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTWK | FEMY |
|---|---|---|
| Founded | 1997 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.0M | 37.2M |
| IPO Year | 1997 | 2021 |
| Metric | NTWK | FEMY |
|---|---|---|
| Price | $3.33 | $0.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.83 |
| AVG Volume (30 Days) | 51.8K | ★ 523.5K |
| Earning Date | 05-22-2026 | 02-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 316.67 | 8.60 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $73,088,687.00 | $1,629,108.00 |
| Revenue This Year | N/A | $64.02 |
| Revenue Next Year | N/A | $147.19 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 13.40 | ★ 51.97 |
| 52 Week Low | $2.14 | $0.31 |
| 52 Week High | $5.75 | $1.76 |
| Indicator | NTWK | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 52.38 | 44.74 |
| Support Level | $3.06 | $0.47 |
| Resistance Level | $3.45 | $0.55 |
| Average True Range (ATR) | 0.34 | 0.04 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 28.18 | 66.96 |
NETSOL Technologies Inc is an information technology and enterprise software solutions provider to original equipment manufacturers (OEMs), dealerships, and financial institutions to sell, finance, and lease assets. The firm's products include Transcend Retail, Transcend Finance, Transcend Marketplace, Transcend Consultancy, and Transcend AI Labs, catering to its customers in the different stages of how assets are sold, financed, and leased. Its primary sources of revenue are licensing, subscriptions, modification, enhancement, and support of its suite of financial applications offered to businesses in the finance and leasing space, as well as automotive digital retail. The company has three reportable segments: Asia-Pacific, its key revenue-generating market, North America, and Europe.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.